Nov 20 (Reuters) - Eli Lilly (NYSE:LLY) and Co LLY.N :
* LILLY'S NEUTRALIZING ANTIBODY BAMLANIVIMAB (LY-COV555) RECEIVES INTERIM AUTHORIZATION FROM HEALTH CANADA AS A TREATMENT FOR COVID-19
* ELI LILLY AND CO - ANTICIPATES MANUFACTURING UP TO ONE MILLION DOSES OF BAMLANIVIMAB 700 MG BY END OF 2020
* ELI LILLY AND CO - LILLY IS IN DISCUSSIONS WITH GLOBAL REGULATORS TO MAKE BAMLANIVIMAB AVAILABLE AROUND WORLD
* ELI LILLY - PURSUING AUTHORIZATION FOR BAMLANIVIMAB IN COUNTRIES SUCH AS INDIA, BRAZIL, RUSSIA, ACROSS EUROPE